Vaccination against COVID-19: a challenge in CLL

In this issue of Blood, Herishanu et al report on the efficacy of the BNT162b2 messenger RNA (mRNA) COVID-19 vaccine in untreated and treated patients with chronic lymphocytic leukemia (CLL).(1) Their findings show low response rates to vaccination in CLL, similar to previous reports with other vaccines.

Automated summary

The efficacy of the BNT162b2 mRNA COVID-19 vaccine is limited in CLL patients, with low response rates similar to previous reports with other vaccines.